Skip to main content

Table 1 Differences in p values when using response vs PFS vs overall survival to assess association of outcomes with biomarkers

From: Fool’s gold, lost treasures, and the randomized clinical trial

Agent No. patients P valuesa
Response PFS Survival
P values for differences in outcome for KRAS wild type vs KRAS mutant colorectal cancer patients treated with single agent monoclonal antibody:
Panitumumab [52] 427 <0.0001b <0.0001 >0.05
Cetuximab [53] 30 0.0003 NRc 0.016
Cetuximab [54] 108 0.000001 0.074 0.020
P values for differences in outcome for KRAS wild type vs KRAS mutant colorectal cancer patients treated with combined monoclonal antibody and chemotherapy:
Cetuximab [55] 110 0.0024 0.0009 NR
Cetuximab [56] 69 0.021 0.021 0.15
Cetuximab [35] 256 0.03 0.04 0.06
Cetuximab [57] 540 0.03 0.07 0.44
Cetuximab [58] 88 0.024 0.003 0.0004
Cetuximab [59] 48 0.144 0.048 NR
Cetuximab [36] 315 <0.001 <0.001 0.12
Cetuximab [60] 67 0.07 0.14 0.047
Cetuximab [61] 1,063 0.0005 0.0028 0.0463
Cetuximab [62] 58 0.027 0.024 0.107
P values for differences in outcome for EGFR wild type vs EGFR mutant NSCLC patients treated with single agent tyrosine kinase inhibitor:
Gefitinib or erlotinib [63] 223 <0.0001b <0.0001 0.002
Gefitinib [64] 57 0.002 NR 0.11
Gefitinib [65] 100 0.0017 NR 0.0135
Gefitinib [66] 68 0.0001 NR 0.001
Gefitinib [67] 66 <0.0001 <0.0001 0.0001
Gefitinib [68] 83 0.001 0.002 0.02
Erlotinib [69] 36 0.006 NR 0.045
Erlotinib [70] 116 0.035 NR 0.47
  1. a. Comparison of outcome in mutant vs wild type or p value for interaction between treatment arm on a comparative study and mutation status.
  2. b. Calculated from published data using Fisher’s exact test.
  3. c. NR = not reported.